Review of interleukin-32 and liver disease
Keywords:
IL-32, liver disease, cytokine, NAFLDAbstract
Interleukin-32 (IL-32) is a pro-inflammatory cytokine that was first characterized in2005.it was named IL-32 due to its potent pro-inflammatory effects. IL-32 does not contain a typical hydrophobic signal peptide at the N terminus for secretion, but IL-32 was detected in the supernatant of stimulated cells, how IL-32 is secreted is still not fully understood. Also, it is still unclear through which cell surface receptor IL-32 mediates its function. IL-32 may also have an important function as an intracellular protein55. IL-32, via interactions with some other molecules, has been reported to be involved in various intracellular signaling. The focus of the present review is on the properties of this cytokine in liver diseases. Understanding the involvement of IL-32 in the pathogenesis of liver diseases may assist in identifying novel therapeutic strategies to mitigate or prevent liver diseases.
Downloads
References
Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells. Semin Immunol. 2018;38:40-48.
Auguet T, Bertran L, Binetti J, Aguilar C, Martínez S, Sabench F, Lopez-Dupla JM, Porras JA, Riesco D, Del Castillo D, Richart C Relationship between IL-8 circulating levels and TLR2 hepatic expression in women with morbid obesity and nonalcoholic steatohepatitis. Int J Mol Sci. 21(11):4189.
B. Heinhuis, M. I. Koenders, W. B. van den Berg, M. G. Netea, C. A. Dinarello, and L. A. B. Joosten, “Interleukin 32 (IL-32) contains a typical ????-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1,” The Journal of Biological Chemistry, 2012;vol. 287, no. 8, pp. 5733–5743,
Banini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini AM, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis. Hepatology. 2021;73(4):1290–1306.
Baselli GA, Dongiovanni P, Rametta R, Meroni M, Pelusi S, Maggioni M, Badiali S, Pingitore P, Maurotti S, Montalcini T, Taliento AE, Prati D, Rossi G, Fracanzani AL, Mancina RM, Romeo S, Valenti L Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut. 2020;69(10):1855–1866.
Cayrol C, Girard J-P. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281:154-168.
Choi J-D, Bae S-Y, Hong J-W, et al. Identification of the most active interleukin-32 isoform. Immunology. 2009;126:535-542.
Cordeiro A, Costa R, Andrade N, Silva C, Canabrava N, Pena MJ, Rodrigues I, Andrade S, Ramalho A Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? Clin Res Hepatol Gastroenterol. 2020; 44(4):394–402.
Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 1992;148:597.
Dali-Youcef N, Vix M, Costantino F, El-Saghire H, Lhermitte B, Callari C, D'Agostino J, Perretta S, Paveliu S, Gualtierotti M, Dumeny E, Oudot MA, Jaulin A, Dembélé D, Zeisel MB, Tomasetto C, Baumert TF, Doffoël M Interleukin-32 contributes to human nonalcoholic fatty liver disease and insulin resistance. Hepatol Commun. 2019;3(9):1205–1220.
Darmadi D, Ruslie RH (2021) Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD). Rom J Intern Med. 2020; 59(1):66–72.
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis 2006;65(Suppl. 3):i61e64.
Eslam M, Sanyal AJ, George J International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1.
Fadaei R, Bagheri N, Heidarian E, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNFalpha and IL-6. Cytokine. 2020;125:154832.
Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM Predictive role of interleukin-18 in liver steatosis in obese children. Can J Gastroenterol Hepatol. 2018:3870454.
Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, Long MT Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the ramingham heart study. Clin Gastroenterol Hepatol. 2019; 17(6):1157–1164.e4.
Gastaldelli A, Cusi K From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep2019; 1(4):312–328.
Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65e91.
Hasegawa H, Thomas HJ, Schooley K, Born TL. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane associated protein. Cytokine. 2011;53:74- 83.
Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LA. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012;60(2):321-327.
hoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. 2016;Sci Rep. 6:28814.
Hossain M, Kubes P (2019) Innate immune cells orchestrate the repair of sterile injury in the liver and beyond. Eur J Immunol. 49(6):831–841.
J. W. Kang, Y. S. Park, D. H. Lee et al., “Interleukin-32delta interacts with IL-32beta and inhibits IL-32beta-mediated IL-10 production,” FEBS Letters, 2013,vol. 587, pp. 3776–3781,
J.-W. Kang, Y. S. Park, D. H. Lee et al., “Interaction network mapping among IL-32 isoforms,” Biochimie, 2014;vol. 101, no. 1, pp. 248–251,.
J.-W. Kang, Y. S. Park, D. H. Lee et al., “Intracellular interaction of interleukin (IL)-32???? with protein kinase C???? (PKC????) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells,”The Journal of Biological Chemistry, 2012;vol. 287, no. 42, pp. 35556–35564,.
J.-W. Kang, Y. S. Park, M. S. Kim et al., “Interleukin (IL)- 32????-mediated CCAAT/enhancer-binding protein ???? (C/EBP????) phosphorylation by protein kinase C????(PKC????) abrogates the inhibitory effect of C/EBP???? on IL-10 production,” The Journal of Biological Chemistry, 2013;vol. 288, no. 33, pp. 23650–23658,.
Kang JW, Choi SC, Cho MC, et al. A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology. 2009;128(1Suppl):532.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131-142.
Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22(1):131-142. Doi:S1074-7613(04)00380-2 [pii]
Kristin Roseth Aass, Martin H. Kastnes, Therese Standal. Molecular interactions and functions of IL-32. J Leukoc Biol. 2020;1–17.
Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020; 159(5):1839–1852.
Lang S, Schnabl B Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe 2020;28(2):233–244.
Lefere S, Tacke F Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Rep2019; 1(1):30–43.
Manal Sabry Mohamed, Sameh Ghaly, Karim Hamed Azmy & Ghada Abdelrahman Mohamed. Assessment of interleukin 32 as a novel biomarker for non-alcoholic fatty liver disease. Egyptian Liver Journal.2022;26
Netea MG, Azam T, Ferwerda G, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1- dependent mechanism. Proc Natl Acad Sci U S A. 2005;102(45):16309-16314.
Netea MG, Lewis EC, Azam T, et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci U S A. 2008;105(9):3515-3520.
Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008;181:557e65
Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989;170(4):1409-1414
Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim SH. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A. 2006;103(9):3316-3321.
Pan X, Cao H, Lu J, Shu X, Xiong X, Hong X, et al. Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-kappaB. Mol Immunol 2011;48: 1573e7.
Rabouille C. Pathways of unconventional protein secretion. Trends Cell Biol. 2017;27:230-240.
Ribeiro-Dias F, Saar Gomes R, de Lima Silva LL, Dos Santos JC, Joosten LA. Interleukin 32: a novel player in the control of infectious diseases. J Leukoc Biol. 2017;101:39-52.
S.-H. Kim, S.-Y. Han, T. Azam, D.-Y. Yoon, and C. A. Dinarello, “Interleukin-32: a cytokine and inducer of TNF????,” Immunity, 2005;vol. 22, no. 1, pp. 131–142,.
Schenk M, Krutzik SR, Sieling PA, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy. Nat Med. 2012;18(4):555-563.
Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim- Mitsuyama S, et al. Epithelial overexpression of interleukin- 32alpha in inflammatory bowel disease. Clin Exp Immunol 2007;149:480e6.
Trépo E, Valenti L Update on NAFLD genetics: from new variants to the clinic. J Hepatol. 2020 72(6):1196–1209.
Valenti L, Pelusi S Redefining fatty liver disease classification in 2020. Liver Int. 2020; 40(5):1016–1017
Zahoor M, Westhrin M, Aass KR, et al. Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 2017;1:2656-2666.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
